Anu Agarwal, MD
Cardiovascular Disease (Cardiology) · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 15
Offices
15 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Healdsburg Hospital · Providence Santa Rosa Memorial Hospital · Sutter Lakeside Hospital · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Agarwal’s office to ask if they take your plan before you enroll.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Healdsburg HospitalHealdsburg, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Providence, which runs 54 hospitals in 7 states77% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
- Sutter Lakeside HospitalLakeport, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for Healdsburg Hospital
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 2 the same, 1 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for pneumonia patientsComplications and deaths | 16.5 · 45 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 109 cases | None | Jul 2024 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.8 · 47 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 31 cases | None | Jul 2023 – Jun 2025 |
| Room was "always" clean | 83% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 94% |
| Yes, staff "did" give patients information about help after discharge | 96% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 84% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 95% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.26 to 2.13) · 1,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.48 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.27 (137.92 to 224.62) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 448 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.3 · 245 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,733 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 8,115 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,057 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.37 (0.56 to 4.18) · 2,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0.1 to 3.08) · 772 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.9 to 3.63) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.74 (0.06 to 11.42) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.04 (0.53 to 7.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.8 (0.38 to 3.21) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1) · 7,051 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 77 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.915 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.552 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 288 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.5 · 456 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 431 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.4 (4.9 to 8.3) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (8.2 to 12.7) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.8 to 16.7) · 2,810 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 780 cases | No different | Jan 2024 – Dec 2024 |
What patients said (473 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Sutter Lakeside Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 8.7 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 94 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 133 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 379 cases | None | Jul 2024 – Jun 2025 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 31 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.249 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -25.4 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -37.9 · 137 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 109 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.3) · 564 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (209 patients answered, 18% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 83% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 82% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 58% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$367,190
Medicare paid this office $367,190 for 2,053 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 327 | $53,306 | $161 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 131 | $52,525 | $398 |
| Long return visit (40+ min) | 212 | $47,341 | $140 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 508 | $30,534 | $51 |
| Return visit (30+ min) | 245 | $27,062 | $98 |
See all 38 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 327 | $53,306 | $161 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 131 | $52,525 | $398 |
| Long return visit (40+ min) | 212 | $47,341 | $140 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 508 | $30,534 | $51 |
| Return visit (30+ min) | 245 | $27,062 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 112 | $20,408 | $96 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 131 | $19,740 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 120 | $17,477 | $139 |
| Critical care, first 30-74 minutes | 27 | $9,685 | $170 |
| New patient visit (60+ min) | 53 | $8,412 | $159 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 17 | $7,732 | $82 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 559 | $7,700 | $12 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 122 | $7,622 | $61 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 327 | $6,784 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 118 | $6,526 | $55 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 339 | $6,256 | $14 |
| Ultrasound of heart with probe in esophagus, with report | 50 | $4,753 | $85 |
| New patient visit (45+ min) | 37 | $4,349 | $118 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 477 | $4,088 | $7 |
| External shock to heart to regulate heart beat | 25 | $2,657 | $89 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 48 | $2,006 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 39 | $1,910 | $21 |
| Ultrasound of heart, follow-up | 67 | $1,689 | $20 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 41 | $1,658 | $26 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 65 | $1,278 | $18 |
| Programming of dual lead pacemaker system | 16 | $1,253 | $63 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 32 | $1,152 | $25 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 35 | $1,017 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $778 | $65 |
| Injection, regadenoson, 0.1 mg | 56 | $770 | None |
| Ultrasound of heart blood flow, valves and chambers | 40 | $640 | $14 |
| Heart rhythm recording of continous external ekg over 8-15 days | 57 | $554 | $9 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 25 | $520 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 18 | $313 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 64 | $187 | $2 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 15 | $171 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 15 | $170 | $11 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 26 | $162 | $6 |
Who their Medicare patients are
2,053 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 13% · Women 53% · Also on Medicaid 25% · Health risk score 1.62. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 41% · Atrial fibrillation 37% · Heart failure 31% · Chronic kidney disease 29% · Diabetes 28% · Depression 24% · COPD 21% · Stroke 16% · Cancer 15% · Dementia 9%.
The office billed $1,988,766, Medicare allowed $491,950 and paid $367,190; for 6,070 services of 53 kinds; $770 of it was for drugs given in the office and $366,420 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,053 | 6,070 | 75 | 1.62 | $1,988,766 | $367,190 |
| 2023 | 1,321 | 4,325 | 75 | 1.62 | $1,746,496 | $351,569 |
| 2022 | 1,180 | 3,566 | 75 | 1.54 | $1,463,320 | $312,554 |
| 2021 | 1,973 | 3,438 | 74 | 1.71 | $775,749 | $184,543 |
| 2020 | 1,828 | 3,167 | 74 | 1.74 | $716,853 | $155,397 |
| 2019 | 2,334 | 4,201 | 74 | 1.73 | $951,342 | $207,467 |
| 2018 | 2,353 | 3,997 | 73 | 1.76 | $859,651 | $190,572 |
| 2017 | 985 | 1,976 | 73 | 1.67 | $449,235 | $109,274 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 34 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 357 | $61,270 | $166 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 113 | $46,803 | $411 |
| Long return visit (40+ min) | 228 | $45,949 | $143 |
| New patient visit (60+ min) | 142 | $24,102 | $170 |
| Return visit (30+ min) | 210 | $23,533 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 299 | $21,074 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 112 | $20,157 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 121 | $17,014 | $137 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 112 | $16,879 | $76 |
| Critical care, first 30-74 minutes | 23 | $7,335 | $179 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 495 | $7,237 | $12 |
| New patient visit (45+ min) | 54 | $6,140 | $114 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 90 | $5,680 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 98 | $5,206 | $53 |
| Injection, regadenoson, 0.1 mg | 29 | $5,156 | None |
| Ultrasound of heart with probe in esophagus, with report | 42 | $3,792 | $90 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 164 | $3,635 | $22 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 23 | $3,230 | $38 |
| External shock to heart to regulate heart beat | 32 | $3,143 | $90 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 53 | $2,081 | $27 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 23 | $1,884 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 39 | $1,544 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 46 | $1,524 | $18 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,481 | $67 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 69 | $1,378 | $17 |
| Ultrasound of heart, follow-up | 36 | $1,078 | $21 |
| Heart rhythm recording of continous external ekg over 8-15 days | 92 | $1,066 | $11 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 27 | $1,014 | $26 |
| Programming of dual lead pacemaker system | 11 | $877 | $73 |
| Ultrasound of heart blood flow, valves and chambers | 38 | $605 | $15 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 32 | $343 | $10 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 11 | $239 | $22 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 11 | $178 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 45 | $121 | $3 |
2022: 33 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 404 | $69,431 | $169 |
| Long return visit (40+ min) | 144 | $31,950 | $151 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 70 | $29,500 | $421 |
| Return visit (30+ min) | 170 | $23,815 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 128 | $20,276 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 120 | $19,346 | $84 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 280 | $16,533 | $57 |
| New patient visit (60+ min) | 87 | $15,419 | $177 |
| New patient visit (45+ min) | 120 | $14,343 | $120 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 70 | $12,019 | $87 |
| Critical care, first 30-74 minutes | 27 | $8,225 | $179 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 105 | $6,645 | $63 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 339 | $5,245 | $12 |
| Injection, regadenoson, 0.1 mg | 20 | $3,759 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $3,444 | $58 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 65 | $3,382 | $52 |
| Ultrasound of heart with probe in esophagus, with report | 29 | $2,505 | $86 |
| External shock to heart to regulate heart beat | 21 | $2,232 | $93 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 54 | $1,769 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 45 | $1,748 | $23 |
| Extended patient service without direct patient contact, first hour | 16 | $1,687 | $94 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 77 | $1,601 | $20 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 59 | $1,325 | $19 |
| Programming of dual lead pacemaker system | 12 | $1,059 | $71 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 24 | $791 | $28 |
| Ultrasound of heart, follow-up | 34 | $775 | $21 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 13 | $723 | $20 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $607 | $18 |
| Heart rhythm recording of continous external ekg over 8-15 days | 45 | $559 | $12 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $500 | $33 |
| Ultrasound of heart blood flow, valves and chambers | 31 | $460 | $15 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 29 | $419 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 30 | $77 | $3 |
2021: 33 services
| Return visit (30+ min) | 262 | $26,964 | $88 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 452 | $24,202 | $53 |
| Long return visit (40+ min) | 124 | $22,373 | $143 |
| New patient visit (45+ min) | 102 | $13,890 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $12,863 | $155 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 68 | $12,385 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $9,784 | $86 |
| New patient visit (60+ min) | 50 | $9,194 | $184 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 15 | $6,760 | $451 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 671 | $5,071 | $6 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 80 | $4,361 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 328 | $4,343 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $2,847 | $59 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 15 | $2,706 | $90 |
| Critical care, first 30-74 minutes | 12 | $2,216 | $185 |
| Ultrasound of heart with probe in esophagus, with report | 25 | $2,156 | $86 |
| External shock to heart to regulate heart beat | 19 | $1,924 | $92 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 60 | $1,574 | $26 |
| Ultrasound of both sides of head and neck blood flow | 41 | $1,164 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 108 | $1,102 | $10 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 59 | $1,031 | $17 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 12 | $802 | $57 |
| Ultrasound of heart, follow-up | 40 | $758 | $19 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $475 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 17 | $410 | $24 |
| Ultrasound of leg arteries or artery grafts | 14 | $381 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 14 | $368 | $26 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 14 | $342 | $16 |
| Ultrasound study of arm and leg arteries | 31 | $289 | $9 |
| Ultrasound of one leg arteries or artery grafts | 11 | $238 | $20 |
| Heart rhythm recording of continous external ekg over 8-15 days | 14 | $181 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 30 | $67 | $2 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $67 | $6 |
2020: 29 services
| Long return visit (40+ min) | 314 | $45,902 | $104 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 490 | $28,413 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $11,528 | $160 |
| New patient visit (60+ min) | 69 | $9,687 | $140 |
| Return visit (30+ min) | 92 | $7,051 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 690 | $5,610 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $5,383 | $85 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 87 | $5,347 | $61 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 26 | $4,061 | $156 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 241 | $3,255 | $13 |
| Short return visit (20+ min) | 44 | $2,559 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $2,362 | $59 |
| Extended patient service without direct patient contact, first hour | 23 | $1,994 | $87 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,753 | $67 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 147 | $1,699 | $12 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,627 | $90 |
| External shock to heart to regulate heart beat | 16 | $1,624 | $90 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 21 | $1,375 | $65 |
| Ultrasound of heart, follow-up | 55 | $1,199 | $21 |
| Long return visit (40+ min) | 11 | $1,016 | $92 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 30 | $614 | $20 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 14 | $611 | $44 |
| External ekg recording for more than 48 hours up to 21 days | 30 | $605 | $20 |
| Ultrasound of both sides of head and neck blood flow | 12 | $402 | $33 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 19 | $378 | $16 |
| Short return visit | 12 | $378 | $32 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 11 | $320 | $29 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 29 | $179 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 43 | $116 | $3 |
2019: 31 services
| Long return visit (40+ min) | 368 | $60,431 | $105 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 675 | $39,033 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $13,613 | $84 |
| New patient visit (60+ min) | 83 | $11,705 | $141 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $11,230 | $160 |
| Return visit (30+ min) | 144 | $10,463 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 783 | $6,249 | $7 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 95 | $5,751 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 423 | $5,542 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $4,780 | $58 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 69 | $4,408 | $64 |
| Ultrasound of heart with probe in esophagus, with report | 42 | $3,863 | $86 |
| Critical care, first 30-74 minutes | 12 | $2,624 | $175 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,544 | $111 |
| Extended patient service without direct patient contact, first hour | 26 | $2,530 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 223 | $2,510 | $11 |
| Extended patient service without direct patient contact, first hour | 23 | $2,259 | $90 |
| External shock to heart to regulate heart beat | 19 | $1,969 | $86 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 25 | $1,393 | $56 |
| Return visit (30+ min) | 21 | $1,350 | $59 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 16 | $1,099 | $69 |
| Ultrasound of heart, follow-up | 50 | $1,012 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 18 | $956 | $48 |
| Short return visit (20+ min) | 16 | $843 | $53 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 32 | $668 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 32 | $658 | $21 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 31 | $641 | $14 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $350 | $32 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 15 | $145 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 50 | $136 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 17 | $102 | $6 |
2018: 25 services
| Long return visit (40+ min) | 246 | $36,864 | $105 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 605 | $34,847 | $57 |
| Return visit (30+ min) | 263 | $24,699 | $75 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $15,336 | $158 |
| New patient visit (60+ min) | 95 | $14,051 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $12,998 | $82 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 128 | $8,098 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 921 | $7,249 | $7 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 93 | $5,556 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 300 | $4,119 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $3,860 | $58 |
| New patient visit (45+ min) | 28 | $3,398 | $121 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 213 | $2,436 | $11 |
| Ultrasound of heart with probe in esophagus, with report | 19 | $1,754 | $88 |
| Ultrasound of heart, follow-up | 69 | $1,462 | $20 |
| New patient visit (60+ min) | 11 | $1,436 | $131 |
| Short return visit (20+ min) | 27 | $1,258 | $47 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 15 | $1,038 | $69 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 37 | $771 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 37 | $762 | $21 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 13 | $651 | $50 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 28 | $464 | $15 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $439 | $31 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 17 | $101 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $54 | $3 |
2017: 24 services
| New patient visit (45+ min) | 129 | $15,769 | $122 |
| Return visit (30+ min) | 133 | $14,847 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $13,993 | $84 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 237 | $12,036 | $51 |
| New patient visit (60+ min) | 50 | $7,656 | $153 |
| Long return visit (40+ min) | 43 | $6,035 | $112 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 64 | $4,252 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $4,231 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,231 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,296 | $110 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 331 | $2,704 | $7 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 34 | $2,687 | $79 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 41 | $2,553 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 171 | $2,272 | $13 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,325 | $88 |
| New patient visit (30+ min) | 14 | $1,220 | $87 |
| Short return visit (20+ min) | 20 | $1,098 | $55 |
| Return visit (30+ min) | 11 | $1,009 | $63 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 65 | $747 | $11 |
| External ekg recording for more than 48 hours up to 21 days | 31 | $676 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 31 | $670 | $22 |
| Ultrasound of heart, follow-up | 19 | $394 | $21 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $89 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $38 | $3 |
Medicaid work
$54,877 in 2024
Medicaid paid $54,877 for 1,156 billed services this clinician did in 2024, up to 134 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 363 | $32,318 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 510 | $10,780 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 130 | $3,859 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 32 | $3,341 |
| Long return visit (40+ min) | 31 | $2,065 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 67 | $2,014 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 23 | $499 |
| 2024 | 1,156 | 7 | 134 | $54,877 |
| 2023 | 738 | 5 | 51 | $54,154 |
| 2022 | 660 | 4 | 55 | $45,979 |
| 2021 | 676 | 5 | 76 | $14,589 |
| 2020 | 688 | 4 | 51 | $13,017 |
| 2019 | 963 | 5 | 71 | $16,534 |
| 2018 | 813 | 3 | 54 | $8,875 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 461 | $44,569 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 189 | $5,955 |
| External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation | 41 | $1,338 |
| Long return visit (40+ min) | 24 | $1,310 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 23 | $982 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 405 | $37,421 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 160 | $4,619 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 69 | $2,898 |
| Return visit (30+ min) | 26 | $1,041 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 197 | $8,002 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 14 | $2,458 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 385 | $1,976 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 66 | $1,353 |
| Return visit (30+ min) | 14 | $800 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 182 | $6,436 |
| Long return visit (40+ min) | 46 | $3,811 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 442 | $2,593 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 18 | $177 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 284 | $9,640 |
| Long return visit (40+ min) | 47 | $3,325 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 544 | $2,691 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 70 | $725 |
| CARDIOVASCULAR STRESS TEST | 18 | $153 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 190 | $5,474 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 601 | $3,289 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 22 | $112 |
Drugs they prescribed that Part D paid
$680,141
Pharmacies billed $680,141 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,249) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
2,661 generic and 588 brand-name prescriptions · $680,141 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 413 | $458,979 | $1,111 |
| Entresto | 76 | $79,225 | $1,042 |
| Farxiga | 25 | $25,781 | $1,031 |
| Xarelto | 18 | $24,522 | $1,362 |
| Repatha Sureclick | 18 | $18,617 | $1,034 |
See all 40 drugs
| Eliquis | 413 | $458,979 | $1,111 |
| Entresto | 76 | $79,225 | $1,042 |
| Farxiga | 25 | $25,781 | $1,031 |
| Xarelto | 18 | $24,522 | $1,362 |
| Repatha Sureclick | 18 | $18,617 | $1,034 |
| Praluent | 12 | $15,018 | $1,252 |
| Atorvastatin | 485 | $5,714 | $12 |
| Metoprolol | 262 | $3,424 | $13 |
| Dofetilide | 31 | $3,206 | $103 |
| Diltiazem 24hr Er (Cd) | 116 | $3,155 | $27 |
| Rosuvastatin | 96 | $2,456 | $26 |
| Ranolazine Er | 28 | $1,640 | $59 |
| Metoprolol | 187 | $1,602 | $9 |
| Flecainide Acetate | 42 | $1,494 | $36 |
| Amiodarone | 16 | $1,445 | $90 |
| Carvedilol | 115 | $1,356 | $12 |
| Losartan | 161 | $1,309 | $8 |
| Amlodipine Besylate | 159 | $1,047 | $7 |
| Lisinopril | 111 | $979 | $9 |
| Isosorbide Mononitrate Er | 78 | $894 | $11 |
| Clopidogrel | 57 | $882 | $15 |
| Hydrochlorothiazide | 87 | $794 | $9 |
| Bisoprolol | 22 | $641 | $29 |
| Valsartan | 19 | $615 | $32 |
| Hydralazine | 31 | $546 | $18 |
| Furosemide | 121 | $502 | $4 |
| Sotalol | 33 | $459 | $14 |
| Nitroglycerin | 46 | $400 | $9 |
| Spironolactone | 52 | $399 | $8 |
| Benazepril | 25 | $388 | $16 |
| Potassium Chloride | 26 | $362 | $14 |
| Fludrocortisone Acetate | 13 | $352 | $27 |
| Propranolol | 16 | $317 | $20 |
| Ezetimibe | 18 | $273 | $15 |
| Doxazosin Mesylate | 15 | $200 | $13 |
| Metolazone | 12 | $185 | $15 |
| Digoxin | 26 | $182 | $7 |
| Cartia Xt | 12 | $145 | $12 |
| Sotalol Af | 11 | $106 | $10 |
| Pantoprazole | 17 | $89 | $5 |
Year by year
| 2024 | 3,249 | 441 | 0% (0) | 18% | $680,141 |
| 2023 | 2,665 | 385 | 0% (0) | 16% | $526,725 |
| 2022 | 1,811 | 383 | 0% (0) | 16% | $306,225 |
| 2021 | 2,916 | 512 | 0% (0) | 14% | $388,950 |
| 2020 | 3,707 | 516 | 0% (0) | 15% | $464,330 |
| 2019 | 3,344 | 490 | 0% (0) | 14% | $363,550 |
| 2018 | 2,275 | 392 | 0% (0) | 17% | $187,583 |
| 2017 | 568 | 133 | 0% (0) | 18% | $21,929 |
| 2016 | 31 | None | 0% (0) | None | $252 |
| 2015 | 89 | 19 | 0% (0) | 26% | $4,210 |
| 2014 | 770 | 51 | 0% (0) | 25% | $28,141 |
| 2013 | 759 | 86 | None | 18% | $22,551 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Eliquis | 299 | $340,079 | $1,137 |
| Entresto | 56 | $70,687 | $1,262 |
| Xarelto | 23 | $27,916 | $1,214 |
| Brilinta | 25 | $19,430 | $777 |
| Praluent | 11 | $12,441 | $1,131 |
| Repatha Sureclick | 11 | $11,893 | $1,081 |
| Diltiazem 24hr Er (Cd) | 108 | $5,915 | $55 |
| Atorvastatin | 326 | $5,072 | $16 |
| Metoprolol | 218 | $4,399 | $20 |
| Ranolazine Er | 21 | $2,311 | $110 |
| Losartan | 130 | $1,904 | $15 |
| Amlodipine Besylate | 172 | $1,640 | $10 |
| Metoprolol | 173 | $1,594 | $9 |
| Flecainide Acetate | 34 | $1,449 | $43 |
| Carvedilol | 125 | $1,372 | $11 |
| Lisinopril | 122 | $1,230 | $10 |
| Rosuvastatin | 79 | $1,213 | $15 |
| Isosorbide Mononitrate Er | 78 | $1,012 | $13 |
| Hydrochlorothiazide | 115 | $1,006 | $9 |
| Amiodarone | 23 | $971 | $42 |
| Clopidogrel | 46 | $838 | $18 |
| Hydralazine | 32 | $783 | $24 |
| Potassium Chloride | 28 | $751 | $27 |
| Furosemide | 95 | $642 | $7 |
| Bisoprolol | 16 | $535 | $33 |
| Sotalol | 19 | $499 | $26 |
| Spironolactone | 36 | $473 | $13 |
| Cartia Xt | 20 | $440 | $22 |
| Nitroglycerin | 25 | $413 | $17 |
| Digoxin | 18 | $384 | $21 |
| Warfarin | 15 | $308 | $21 |
| Fludrocortisone Acetate | 14 | $298 | $21 |
| Propranolol | 11 | $266 | $24 |
| Midodrine | 11 | $264 | $24 |
2022: 28 drugs
| Eliquis | 167 | $169,863 | $1,017 |
| Xarelto | 42 | $50,026 | $1,191 |
| Entresto | 31 | $24,140 | $779 |
| Repatha Sureclick | 14 | $14,872 | $1,062 |
| Brilinta | 11 | $5,840 | $531 |
| Atorvastatin | 254 | $3,287 | $13 |
| Metoprolol | 136 | $3,054 | $22 |
| Diltiazem 24hr Er (Cd) | 54 | $2,493 | $46 |
| Metoprolol | 131 | $1,525 | $12 |
| Carvedilol | 95 | $1,130 | $12 |
| Flecainide Acetate | 26 | $1,034 | $40 |
| Rosuvastatin | 46 | $942 | $20 |
| Clopidogrel | 31 | $899 | $29 |
| Lisinopril | 84 | $830 | $10 |
| Digoxin | 31 | $749 | $24 |
| Isosorbide Mononitrate Er | 50 | $722 | $14 |
| Losartan | 65 | $719 | $11 |
| Amlodipine Besylate | 86 | $626 | $7 |
| Potassium Chloride | 20 | $579 | $29 |
| Hydralazine | 28 | $509 | $18 |
| Furosemide | 90 | $490 | $5 |
| Hydrochlorothiazide | 62 | $425 | $7 |
| Nitroglycerin | 20 | $398 | $20 |
| Sotalol | 14 | $329 | $23 |
| Ezetimibe | 12 | $261 | $22 |
| Spironolactone | 13 | $197 | $15 |
| Warfarin | 15 | $161 | $11 |
| Verapamil Er | 15 | $152 | $10 |
2021: 35 drugs
| Eliquis | 181 | $191,187 | $1,056 |
| Xarelto | 65 | $83,893 | $1,291 |
| Pradaxa | 18 | $14,354 | $797 |
| Praluent | 17 | $7,632 | $449 |
| Atorvastatin | 342 | $5,328 | $16 |
| Flecainide Acetate | 84 | $3,887 | $46 |
| Diltiazem 24hr Er (Cd) | 67 | $3,267 | $49 |
| Metoprolol | 162 | $3,234 | $20 |
| Losartan | 151 | $2,505 | $17 |
| Amiodarone | 33 | $2,274 | $69 |
| Rosuvastatin | 130 | $2,230 | $17 |
| Carvedilol | 205 | $2,194 | $11 |
| Ezetimibe | 32 | $1,951 | $61 |
| Digoxin | 58 | $1,862 | $32 |
| Metoprolol | 147 | $1,755 | $12 |
| Amlodipine Besylate | 165 | $1,533 | $9 |
| Diltiazem 24hr Er | 13 | $1,173 | $90 |
| Potassium Chloride | 42 | $1,158 | $28 |
| Furosemide | 162 | $1,031 | $6 |
| Isosorbide Mononitrate Er | 62 | $987 | $16 |
| Hydrochlorothiazide | 108 | $864 | $8 |
| Lisinopril | 126 | $837 | $7 |
| Spironolactone | 54 | $691 | $13 |
| Prasugrel | 13 | $684 | $53 |
| Sotalol | 35 | $641 | $18 |
| Cartia Xt | 13 | $613 | $47 |
| Clopidogrel | 47 | $566 | $12 |
| Bumetanide | 14 | $546 | $39 |
| Pravastatin | 25 | $439 | $18 |
| Dilt-Xr | 13 | $379 | $29 |
| Nitroglycerin | 27 | $371 | $14 |
| Pantoprazole | 11 | $327 | $30 |
| Hydralazine | 30 | $318 | $11 |
| Atenolol | 31 | $271 | $9 |
| Simvastatin | 32 | $198 | $6 |
2020: 44 drugs
| Eliquis | 258 | $225,282 | $873 |
| Xarelto | 115 | $110,308 | $959 |
| Multaq | 20 | $27,167 | $1,358 |
| Pradaxa | 12 | $10,302 | $858 |
| Atorvastatin | 391 | $6,235 | $16 |
| Flecainide Acetate | 63 | $5,494 | $87 |
| Metoprolol | 213 | $5,374 | $25 |
| Diltiazem 24hr Er (Cd) | 66 | $3,579 | $54 |
| Losartan | 187 | $3,544 | $19 |
| Rosuvastatin | 118 | $3,114 | $26 |
| Carvedilol | 259 | $2,598 | $10 |
| Metoprolol | 245 | $2,379 | $10 |
| Digoxin | 71 | $2,148 | $30 |
| Ezetimibe | 33 | $1,849 | $56 |
| Potassium Chloride | 56 | $1,465 | $26 |
| Diltiazem 24hr Er | 26 | $1,394 | $54 |
| Amiodarone | 49 | $1,382 | $28 |
| Amlodipine Besylate | 171 | $1,351 | $8 |
| Cartia Xt | 48 | $1,314 | $27 |
| Sotalol | 36 | $1,196 | $33 |
| Isosorbide Mononitrate Er | 53 | $1,092 | $21 |
| Lisinopril | 167 | $1,063 | $6 |
| Furosemide | 178 | $954 | $5 |
| Pravastatin | 42 | $904 | $22 |
| Clopidogrel | 69 | $887 | $13 |
| Hydrochlorothiazide | 144 | $881 | $6 |
| Fenofibrate | 17 | $851 | $50 |
| Spironolactone | 58 | $720 | $12 |
| Nitroglycerin | 46 | $696 | $15 |
| Torsemide | 14 | $685 | $49 |
| Bisoprolol | 14 | $597 | $43 |
| Dilt-Xr | 13 | $575 | $44 |
| Propafenone | 11 | $552 | $50 |
| Hydralazine | 46 | $524 | $11 |
| Benazepril | 32 | $490 | $15 |
| Simvastatin | 72 | $414 | $6 |
| Verapamil Er | 14 | $337 | $24 |
| Doxazosin Mesylate | 15 | $260 | $17 |
| Olmesartan Medoxomil | 11 | $256 | $23 |
| Lovastatin | 13 | $256 | $20 |
| Omeprazole | 22 | $197 | $9 |
| Clonidine | 20 | $161 | $8 |
| Pantoprazole | 11 | $105 | $10 |
| Atenolol | 11 | $104 | $9 |
2019: 44 drugs
| Eliquis | 245 | $176,325 | $720 |
| Xarelto | 71 | $71,729 | $1,010 |
| Multaq | 12 | $18,609 | $1,551 |
| Pradaxa | 18 | $17,915 | $995 |
| Atorvastatin | 347 | $6,064 | $17 |
| Metoprolol | 174 | $4,679 | $27 |
| Diltiazem 24hr Er (Cd) | 57 | $3,973 | $70 |
| Flecainide Acetate | 43 | $3,933 | $91 |
| Metoprolol | 313 | $2,668 | $9 |
| Carvedilol | 260 | $2,466 | $9 |
| Prasugrel | 11 | $2,373 | $216 |
| Midodrine | 14 | $2,216 | $158 |
| Cartia Xt | 70 | $2,146 | $31 |
| Ezetimibe | 32 | $2,023 | $63 |
| Losartan | 171 | $1,991 | $12 |
| Potassium Chloride | 63 | $1,977 | $31 |
| Rosuvastatin | 85 | $1,973 | $23 |
| Digoxin | 55 | $1,770 | $32 |
| Amiodarone | 47 | $1,649 | $35 |
| Amlodipine Besylate | 191 | $1,375 | $7 |
| Lisinopril | 149 | $1,179 | $8 |
| Pravastatin | 52 | $1,090 | $21 |
| Diltiazem 24hr Er | 17 | $956 | $56 |
| Sotalol | 21 | $752 | $36 |
| Clopidogrel | 44 | $750 | $17 |
| Isosorbide Mononitrate Er | 50 | $749 | $15 |
| Digitek | 17 | $739 | $43 |
| Hydrochlorothiazide | 120 | $728 | $6 |
| Furosemide | 117 | $544 | $5 |
| Spironolactone | 48 | $530 | $11 |
| Digox | 16 | $522 | $33 |
| Simvastatin | 61 | $448 | $7 |
| Bisoprolol | 14 | $412 | $29 |
| Torsemide | 18 | $365 | $20 |
| Nitroglycerin | 25 | $355 | $14 |
| Verapamil Er | 11 | $330 | $30 |
| Omeprazole | 20 | $303 | $15 |
| Irbesartan | 19 | $264 | $14 |
| Benazepril | 21 | $241 | $11 |
| Atenolol | 15 | $179 | $12 |
| Losartan-Hydrochlorothiazide | 16 | $162 | $10 |
| Hydralazine | 18 | $159 | $9 |
| Pantoprazole | 15 | $150 | $10 |
| Clonidine | 14 | $131 | $9 |
2018: 34 drugs
| Eliquis | 133 | $74,442 | $560 |
| Xarelto | 49 | $28,850 | $589 |
| Praluent | 17 | $19,842 | $1,167 |
| Brilinta | 12 | $6,152 | $513 |
| Metoprolol | 132 | $3,827 | $29 |
| Atorvastatin | 249 | $3,789 | $15 |
| Diltiazem 24hr Er (Cd) | 30 | $2,442 | $81 |
| Metoprolol | 284 | $2,133 | $8 |
| Digoxin | 49 | $1,756 | $36 |
| Cartia Xt | 76 | $1,684 | $22 |
| Carvedilol | 174 | $1,366 | $8 |
| Ezetimibe | 16 | $1,335 | $83 |
| Flecainide Acetate | 14 | $1,037 | $74 |
| Potassium Chloride | 44 | $1,018 | $23 |
| Amlodipine Besylate | 133 | $887 | $7 |
| Rosuvastatin | 37 | $718 | $19 |
| Digitek | 14 | $708 | $51 |
| Lisinopril | 136 | $700 | $5 |
| Digox | 23 | $677 | $29 |
| Pravastatin | 34 | $664 | $20 |
| Losartan | 72 | $645 | $9 |
| Clopidogrel | 37 | $539 | $15 |
| Amiodarone | 28 | $414 | $15 |
| Nitroglycerin | 27 | $367 | $14 |
| Hydrochlorothiazide | 59 | $359 | $6 |
| Furosemide | 80 | $285 | $4 |
| Losartan-Hydrochlorothiazide | 14 | $250 | $18 |
| Omeprazole | 20 | $215 | $11 |
| Spironolactone | 24 | $210 | $9 |
| Isosorbide Mononitrate Er | 16 | $194 | $12 |
| Irbesartan | 12 | $177 | $15 |
| Simvastatin | 21 | $174 | $8 |
| Benazepril | 11 | $79 | $7 |
| Atenolol | 11 | $75 | $7 |
2017: 16 drugs
| Eliquis | 16 | $9,239 | $577 |
| Atorvastatin | 91 | $1,181 | $13 |
| Metoprolol | 25 | $715 | $29 |
| Metoprolol | 92 | $638 | $7 |
| Digoxin | 14 | $426 | $30 |
| Cartia Xt | 13 | $338 | $26 |
| Carvedilol | 37 | $278 | $8 |
| Nitroglycerin | 15 | $277 | $18 |
| Amlodipine Besylate | 33 | $240 | $7 |
| Furosemide | 44 | $171 | $4 |
| Clopidogrel | 11 | $144 | $13 |
| Lisinopril | 25 | $134 | $5 |
| Losartan | 14 | $111 | $8 |
| Pravastatin | 12 | $97 | $8 |
| Hydrochlorothiazide | 12 | $90 | $7 |
| Atenolol | 11 | $17 | $2 |
2014: 19 drugs
| Effient | 15 | $5,001 | $333 |
| Crestor | 11 | $2,448 | $223 |
| Metoprolol | 42 | $1,464 | $35 |
| Atorvastatin | 76 | $1,185 | $16 |
| Amiodarone | 28 | $1,083 | $39 |
| Eplerenone | 12 | $1,022 | $85 |
| Clopidogrel | 46 | $771 | $17 |
| Digoxin | 18 | $645 | $36 |
| Carvedilol | 52 | $374 | $7 |
| Lisinopril | 88 | $314 | $4 |
| Nitrostat | 18 | $279 | $15 |
| Furosemide | 75 | $256 | $3 |
| Isosorbide Mononitrate Er | 14 | $231 | $16 |
| Losartan | 26 | $224 | $9 |
| Amlodipine Besylate | 34 | $155 | $5 |
| Metoprolol | 37 | $117 | $3 |
| Hydrochlorothiazide | 25 | $114 | $5 |
| Omeprazole | 14 | $94 | $7 |
| Spironolactone | 14 | $89 | $6 |
2013: 16 drugs
| Brilinta | 12 | $2,896 | $241 |
| Metoprolol | 65 | $2,214 | $34 |
| Clopidogrel | 53 | $1,629 | $31 |
| Atorvastatin | 61 | $1,208 | $20 |
| Amiodarone | 15 | $628 | $42 |
| Losartan | 25 | $374 | $15 |
| Nitrostat | 20 | $334 | $17 |
| Isosorbide Mononitrate Er | 23 | $281 | $12 |
| Metoprolol | 42 | $272 | $6 |
| Simvastatin | 33 | $238 | $7 |
| Carvedilol | 36 | $230 | $6 |
| Lisinopril | 69 | $227 | $3 |
| Furosemide | 45 | $191 | $4 |
| Digoxin | 31 | $153 | $5 |
| Spironolactone | 19 | $135 | $7 |
| Hydrochlorothiazide | 37 | $88 | $2 |
Money from drug and device companies
$646 in 2025
| 2025 | 11 | 15 | None | $646 |
| 2024 | 5 | 9 | None | $364 |
| 2023 | 1 | 3 | None | $24 |
| 2022 | 3 | 7 | None | $103 |
| 2021 | 2 | 2 | None | $26 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Micra | $325 | 3 payments
|
| Abbott Laboratories | Amplatzer Amulet | $55 | 2 payments
|
| Philips North America | Mcot | $46 | 1 payment
|
| Stryker | Flowtriever Catheter, S | $42 | 1 payment
|
| Octapharma USA | Fibryga | $36 | 2 payments
|
| Amgen | Repatha | $32 | 1 payment
|
See all 15 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-04 | Jardiance | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-14 | Camzyos | $29 |
| Medtronic | Meals · 2025-10-01 | Micra | $154 |
| Amgen | Meals · 2025-09-24 | Repatha | $32 |
| Ge Healthcare | Meals · 2025-09-10 | None | $30 |
| Octapharma USA | Meals · 2025-08-07 | Fibryga | $18 |
| Abbott Laboratories | Meals · 2025-07-21 | Amplatzer Amulet | $27 |
| Abbott Laboratories | Meals · 2025-07-21 | Amplatzer Amulet | $27 |
| Octapharma USA | Meals · 2025-07-16 | Fibryga | $18 |
| Medtronic | Meals · 2025-07-10 | Symplicity G3 | $135 |
| Pfizer | Meals · 2025-05-08 | Vyndaqel | $23 |
| Stryker | Meals · 2025-04-29 | Flowtriever Catheter, S | $42 |
| Philips North America | Meals · 2025-04-18 | Mcot | $46 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-03-18 | Lifevest | $6 |
| Medtronic | Meals · 2025-03-04 | Micra | $36 |
See earlier years (2024, 2023, 2022, 2021)
2024: $364
| E.R. Squibb & Sons L.L.C. | Camzyos | $150 | 5 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $140 | 1 payment
|
| Philips North America | (5044) Mcot | $43 | 1 payment
|
| iRhythm Technologies | Zio Xt Patch | $25 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $6 | 1 payment
|
2023: $24
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $24 | 3 payments
|
2022: $103
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $50 | 5 payments
|
| HeartFlow | Ffrct | $30 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $23 | 1 payment
|
2021: $26
| HeartFlow | Ffrct | $19 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $7 | 1 payment
|
Professional record
- NPI
- 1639345481
- Licence
- NV 16763
- Trained
- Albany Medical College of Union University, 2008
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- NV 1639345481
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2008-05-01
- NPI last updated
- 2024-07-29
- NPI record certified
- 2024-07-29
This is when the NPI record was last certified, not a medical board exam.